Freenome announced a SPAC merger expected to deliver roughly $330 million in proceeds, backed by a $240 million PIPE from institutional healthcare investors. The Bay Area developer is preparing for potential commercialization in 2026 of SimpleScreen, its blood-based colorectal cancer screening test currently under FDA review. Management cited pivotal PREEMPT CRC data and commercial partnerships as drivers for the public listing, positioning Freenome to compete with established liquid‑biopsy firms. The transaction is slated to complete by H1 2026, with an anticipated Nasdaq ticker. Sources: company press releases and STAT/MedCity reporting.